ERBB2 and breast cancer: Among these subtypes, HER2-/ hormone receptor-positive (HR+) (i.e., ER and/or PR-positive) BC is the most common and least invasive one, accounting for 60%–65% of BC in China and 70% in Europe and America [2, 3].